The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.

Kullavanuaya P, Treeprasertsuk S, Thong-Ngam D, Chaermthai K, Gonlachanvit S, Suwanagool P

Journal of the Medical Association of Thailand = Chotmaihet thangphaet1 Jun 2001Cited by 8 (Europe PMC)

PMID11529376PepBankPUB-11529376

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, serum AST was significantly lower at weeks 24 and 48 of interferon alpha-2a with thymosin alpha1 than before treatment.
In plain wordsIn people with chronic hepatitis C, a liver enzyme (AST) fell during treatment with interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
DecreaseSerum AST at weeks 24 and 48
Study
n = 12
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Serum AST, ALT, and HCV-RNA levels were significantly lower at week 24 and 48 after treatment compared to before treatment (p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937601
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, serum ALT was significantly lower at weeks 24 and 48 of interferon alpha-2a with thymosin alpha1 than before treatment.
In plain wordsIn people with chronic hepatitis C, a liver enzyme (ALT) fell during treatment with interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
DecreaseSerum ALT at weeks 24 and 48
Study
n = 12
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Serum AST, ALT, and HCV-RNA levels were significantly lower at week 24 and 48 after treatment compared to before treatment (p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937602
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, serum HCV-RNA was significantly lower at weeks 24 and 48 of interferon alpha-2a with thymosin alpha1 than before treatment.
In plain wordsIn people with chronic hepatitis C, hepatitis C virus levels in blood fell during treatment with interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
DecreaseSerum HCV-RNA at weeks 24 and 48
Study
n = 12
Outcome group
Antiviral activity · Infection
Source sentences
Summary
Serum AST, ALT, and HCV-RNA levels were significantly lower at week 24 and 48 after treatment compared to before treatment (p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937603
04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In adults with chronic hepatitis C, myalgia occurred in 33.3% on interferon alpha-2a with thymosin alpha1.
In plain wordsIn people with chronic hepatitis C, a third had muscle pain on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
Not applicableMyalgia
Study
n = 12
Outcome group
Adverse events · Whole body
Measurements
Myalgia
33.3%
combination therapy
Source sentences
Summary
Minor side effects were observed during treatment with this combination therapy and these included myalgia (33.3%), mild form of alopecia (33.3%), and weight loss (8.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937609
05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In adults with chronic hepatitis C, mild alopecia occurred in 33.3% on interferon alpha-2a with thymosin alpha1.
In plain wordsIn people with chronic hepatitis C, a third had mild hair loss on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
Not applicableMild alopecia
Study
n = 12
Outcome group
Adverse events · Skin and wound
Measurements
Mild alopecia
33.3%
combination therapy
Source sentences
Summary
Minor side effects were observed during treatment with this combination therapy and these included myalgia (33.3%), mild form of alopecia (33.3%), and weight loss (8.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937610
06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In adults with chronic hepatitis C, weight loss occurred in 8.3% on interferon alpha-2a with thymosin alpha1.
In plain wordsIn people with chronic hepatitis C, 8.3% lost weight on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
Not applicableWeight loss
Study
n = 12
Outcome group
Adverse events · Whole body
Measurements
Weight loss
8.3%
combination therapy
Source sentences
Summary
Minor side effects were observed during treatment with this combination therapy and these included myalgia (33.3%), mild form of alopecia (33.3%), and weight loss (8.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937611
07HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In adults with chronic hepatitis C on interferon alpha-2a with thymosin alpha1, one patient dropped out after 32 weeks of follow-up due to noncompliance.
In plain wordsIn people with chronic hepatitis C, one patient left the study because of not following the treatment plan.
Peptide
Thymosin alpha-1
Outcome
Not applicableDropout due to noncompliance
Study
n = 12
Outcome group
Adverse events · Whole body
Source sentences
Summary
One patient dropped out after 32 weeks of follow-up due to noncompliance.
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937612
08HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, complete HCV-RNA clearance at week 24 of interferon alpha-2a with thymosin alpha1 was noted in 33.3 per cent.
In plain wordsIn people with chronic hepatitis C, the virus was no longer detectable at week 24 in a third of patients on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseComplete HCV-RNA clearance at week 24
Study
n = 11
Outcome group
Antiviral activity · Infection
Measurements
Complete HCV-RNA clearance
33.3%
week 24
Source sentences
Summary
Of 11 cases, complete HCV-RNA clearance at week 24 was noted in 33.3 per cent
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937604
09HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, normal ALT values at week 24 of interferon alpha-2a with thymosin alpha1 were observed in 41.7 per cent of patients.
In plain wordsIn people with chronic hepatitis C, 41.7 per cent had normal liver enzyme levels at week 24 on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseNormal ALT at week 24
Study
n = 11
Outcome group
Liver fat and liver function · Liver
Measurements
Normal ALT
41.7%
week 24
Source sentences
Summary
whereas, normal alanine aminotransferase values (ALT < 40 U/L) were observed in 41.7 per cent of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937605
10HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, complete HCV-RNA clearance at week 48 of interferon alpha-2a with thymosin alpha1 was seen in 45.5 per cent of patients.
In plain wordsIn people with chronic hepatitis C, the virus was no longer detectable at week 48 in 45.5 per cent on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseComplete HCV-RNA clearance at week 48
Study
n = 11
Outcome group
Antiviral activity · Infection
Measurements
Complete HCV-RNA clearance
45.5%
week 48
Source sentences
Summary
Complete HCV-RNA clearance and normal alanine aminotransferase at week 48 were seen in 45.5 per cent of the patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937606
11HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with chronic hepatitis C, normal alanine aminotransferase at week 48 of interferon alpha-2a with thymosin alpha1 was seen in 45.5 per cent of patients.
In plain wordsIn people with chronic hepatitis C, 45.5 per cent had normal liver enzyme levels at week 48 on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseNormal ALT at week 48
Study
n = 11
Outcome group
Liver fat and liver function · Liver
Measurements
Normal ALT
45.5%
week 48
Source sentences
Summary
Complete HCV-RNA clearance and normal alanine aminotransferase at week 48 were seen in 45.5 per cent of the patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937607
12HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In treatment-naive adults with chronic hepatitis C, complete response occurred in 4 of 5 patients at the end of week 48 of interferon alpha-2a with thymosin alpha1.
In plain wordsIn treatment-naive people with chronic hepatitis C, 4 of 5 had a complete response at week 48 on interferon plus thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseComplete response in naive patients at week 48
Study
n = 5
Outcome group
Antiviral activity · Infection
Source sentences
Summary
At the end of week 48, complete response occurred in 4 of 5 naive patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve chronic hepatitis C patients (9 M, 3F), with positive HCV-RNA and histology compatible with chronic hepatitis C were included in this open, prospective study.
Summary · context
Each patient received a combination therapy of IFN alpha 2a 3 mU s.c. TIW and Thymosin alpha1 1.6 mg s.c. twice a week for 52 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1152937608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.